c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins - PubMed (original) (raw)

Affiliations

PMID: 1827665

c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins

R P Ryseck et al. Oncogene. 1991 Apr.

Abstract

We have compared the binding properties of c-JUN, JUN B, and JUN D in the absence or in the presence of c-FOS, FOS B, and FRA-1 to different AP-1 and CRE-containing oligonucleotides. The results demonstrate that for a given AP-1-containing oligonucleotide the binding affinities of the different JUN proteins are always c-JUN greater than JUN D greater than JUN B. The three JUN proteins have the capacity to bind to a CRE consensus sequence with very high affinity. We have found that c-JUN, JUN B, and JUN D bind with different affinities to different oligonucleotides containing an identical AP-1 or CRE binding site, implying that the adjacent sequences influence the stability of the JUN/DNA complexes. Interestingly, an AP-1-containing oligonucleotide which binds the JUN proteins with high affinity can be converted to a CRE-containing oligonucleotide which will also bind the different JUNs very efficiently. The heterodimers formed between the different JUN and FOS proteins have an enhanced binding activity compared to the JUN:JUN homodimers. In all cases the half-lives of the JUN:FOS/DNA complexes are longer than those of the JUN:JUN/DNA complexes. The most stable complexes were obtained in the presence of FOS B, followed by FRA-1 and c-FOS.

PubMed Disclaimer

Cited by

Protein kinase R modulates c-Fos and c-Jun signaling to promote proliferation of hepatocellular carcinoma with hepatitis C virus infection.
Watanabe T, Hiasa Y, Tokumoto Y, Hirooka M, Abe M, Ikeda Y, Matsuura B, Chung RT, Onji M. Watanabe T, et al. PLoS One. 2013 Jul 2;8(7):e67750. doi: 10.1371/journal.pone.0067750. Print 2013. PLoS One. 2013. PMID: 23844083 Free PMC article.
Selective antagonism of cJun for cancer therapy.
Brennan A, Leech JT, Kad NM, Mason JM. Brennan A, et al. J Exp Clin Cancer Res. 2020 Sep 11;39(1):184. doi: 10.1186/s13046-020-01686-9. J Exp Clin Cancer Res. 2020. PMID: 32917236 Free PMC article. Review.
The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB.
Boise LH, Petryniak B, Mao X, June CH, Wang CY, Lindsten T, Bravo R, Kovary K, Leiden JM, Thompson CB. Boise LH, et al. Mol Cell Biol. 1993 Mar;13(3):1911-9. doi: 10.1128/mcb.13.3.1911-1919.1993. Mol Cell Biol. 1993. PMID: 8441422 Free PMC article.
Small molecule inhibitors targeting activator protein 1 (AP-1).
Ye N, Ding Y, Wild C, Shen Q, Zhou J. Ye N, et al. J Med Chem. 2014 Aug 28;57(16):6930-48. doi: 10.1021/jm5004733. Epub 2014 May 27. J Med Chem. 2014. PMID: 24831826 Free PMC article.
12-O-Tetradecanoylphorbol-13-Acetate Induces Up-Regulated Transcription of Variant 1 but Not Variant 2 of VIL2 in Esophageal Squamous Cell Carcinoma Cells via ERK1/2/AP-1/Sp1 Signaling.
Zhang XD, Xie JJ, Liao LD, Long L, Xie YM, Li EM, Xu LY. Zhang XD, et al. PLoS One. 2015 Apr 27;10(4):e0124680. doi: 10.1371/journal.pone.0124680. eCollection 2015. PLoS One. 2015. PMID: 25915860 Free PMC article.

c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins - PubMed (original) (raw)